tiprankstipranks
Anebulo Pharmaceuticals (ANEB)
NASDAQ:ANEB

Anebulo Pharmaceuticals (ANEB) AI Stock Analysis

Compare
24 Followers

Top Page

AN

Anebulo Pharmaceuticals

(NASDAQ:ANEB)

36Underperform
Anebulo Pharmaceuticals faces significant financial hurdles, with consistent losses and no revenue generation. Despite a strong balance sheet with zero debt, the high reliance on equity financing and negative cash flow are critical concerns. Technical analysis shows some positive momentum, but the lack of valuation metrics highlights the risks associated with investing in an early-stage biotech firm. Investors should consider the company's ability to secure future funding and potential for revenue growth.
Positive Factors
Analyst rating
Analyst maintains a Speculative Buy rating on ANEB shares due to the continuing need for a treatment for acute cannabis-induced toxicity and the company’s earlier positive results for its selonabant therapeutic.
Clinical results
The company announced clinical results from a Phase 2 proof-of-concept study with 134 adult subjects using oral selonabant to treat acute cannabis-induced toxicity.
Financial resources
Anebulo has adequate financial resources to fund operations well into calendar year 2026.
Negative Factors
Equity placement
Anebulo completed a $15 million equity private placement during the second quarter and held approximately $15.0 million in cash on hand.
Grant dependency
The company received a $1.9 million grant from the US National Institute on Drug Abuse (NIDA) to support the development of IV selonabant in the emergency treatment of acute cannabis-induced toxicities.
Market focus
Anebulo Pharmaceuticals is focusing on the development of intravenous (IV) selonabant for the treatment of acute cannabis-induced toxic effects, particularly in pediatric cases.

Anebulo Pharmaceuticals (ANEB) vs. S&P 500 (SPY)

Anebulo Pharmaceuticals Business Overview & Revenue Model

Company DescriptionAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
How the Company Makes MoneyAnebulo Pharmaceuticals generates revenue primarily through the development and potential commercialization of its lead product candidate, ANEB-001. As a clinical-stage company, Anebulo's current revenue streams are limited, and it largely relies on funding through public and private investment to support its research and development activities. In the future, the company plans to earn income through licensing agreements, strategic partnerships, and sales of its pharmaceutical products upon receiving regulatory approval. Significant partnerships with larger pharmaceutical companies could also contribute to its revenue by providing milestone payments, royalties, and collaborative research funding.

Anebulo Pharmaceuticals Financial Statement Overview

Summary
Anebulo Pharmaceuticals faces significant financial challenges typical of early-stage biotech companies. With no revenue and consistent losses, the company relies heavily on equity financing to sustain its operations. While the balance sheet is strong due to zero debt, the ongoing cash burn and lack of profitability are major concerns. Investors should be cautious and consider the company's ability to secure future funding and achieve revenue growth.
Income Statement
10
Very Negative
Anebulo Pharmaceuticals has shown consistent net losses over the years, with no revenue generation. The TTM data shows a net income of -$7.67 million, indicating a lack of profitability. The absence of revenue growth and negative EBIT and EBITDA margins highlight the company's struggle to achieve operational efficiency.
Balance Sheet
40
Negative
The company maintains a strong equity base with zero debt, leading to a favorable debt-to-equity ratio. However, the return on equity remains negative due to continuous losses. The equity ratio is high, indicating reliance on equity for funding, which is common in early-stage biotech firms.
Cash Flow
30
Negative
Anebulo has a negative free cash flow, with the TTM free cash flow being -$6.65 million. The operating cash flow to net income ratio is relatively stable, but the company relies heavily on financing activities to sustain operations. This reliance poses a risk if external funding sources dry up.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
0.000.000.000.000.000.00
Gross Profit
0.000.000.000.000.000.00
EBIT
-8.00M-8.31M-11.78M-6.83M-3.61M-173.35K
EBITDA
-7.43M-8.05M-11.78M5.55K-30.24M-173.35K
Net Income Common Stockholders
-7.67M-8.20M-11.73M-6.81M-30.26M-174.64K
Balance SheetCash, Cash Equivalents and Short-Term Investments
15.00M3.09M11.25M14.55M19.99M3.02M
Total Assets
15.84M4.07M11.67M15.58M21.65M3.03M
Total Debt
0.000.000.000.000.00201.29K
Net Debt
-15.00M-3.09M-11.25M-14.55M-19.99M-2.82M
Total Liabilities
878.80K260.58K1.07M512.53K241.63K3.20M
Stockholders Equity
14.96M3.81M10.60M15.07M21.41M-171.14K
Cash FlowFree Cash Flow
-6.65M-8.09M-9.68M-5.44M-4.87M-150.77K
Operating Cash Flow
-6.65M-8.09M-9.68M-5.44M-4.87M-150.77K
Investing Cash Flow
0.000.000.000.000.000.00
Financing Cash Flow
15.00M-62.35K6.38M0.0021.83M3.18M

Anebulo Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.15
Price Trends
50DMA
1.42
Negative
100DMA
1.46
Negative
200DMA
1.78
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
40.11
Neutral
STOCH
7.29
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANEB, the sentiment is Negative. The current price of 1.15 is below the 20-day moving average (MA) of 1.46, below the 50-day MA of 1.42, and below the 200-day MA of 1.78, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.11 is Neutral, neither overbought nor oversold. The STOCH value of 7.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANEB.

Anebulo Pharmaceuticals Risk Analysis

Anebulo Pharmaceuticals disclosed 49 risk factors in its most recent earnings report. Anebulo Pharmaceuticals reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Anebulo Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
49
Neutral
$54.56M-61.03%16.84%9.43%
48
Neutral
$6.86B1.11-50.22%2.47%16.71%1.53%
42
Neutral
$46.48M-110.63%-100.00%30.65%
38
Underperform
$52.31M-121.97%65.54%
37
Underperform
$43.66M-415.84%-74.60%
36
Underperform
$48.89M-71.49%28.92%
29
Underperform
$52.38M-69.01%16.38%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ANEB
Anebulo Pharmaceuticals
1.08
-1.83
-62.89%
ATNM
Actinium Pharmaceuticals
1.39
-7.74
-84.78%
VTVT
vTv Therapeutics
17.49
-8.01
-31.41%
PRLD
Prelude Therapeutics
0.71
-4.03
-85.02%
ALGS
Aligos Therapeutics
6.48
-17.83
-73.34%
HYPR
Hyperfine
0.69
-0.26
-27.37%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.